VICL News Alert Vical Inc (VICL) 1.03 12/25/2014 02:32:37

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vical Inc (VICL) 1.03 $VICL

Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.49 (unch), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), CLDX: 17.08 (-0.18), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), MNTA: 11.42 (-0.06), PVCT: 0.85 (-0.02), VICL: 1.03 (+0.02), AZN: 70.44 (+0.26), DCTH: 1.36 (+0.01), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

Hot Stock: Vical, Shares Drop 6.9% (VICL)
Comtex SmarTrend(R) - Tue Dec 16, 10:09AM CST
Vical (NASDAQ:VICL) is one of today's worst performing penny stocks, down 6.9% to $0.93 on 1.5x average daily volume. Vical has traded 507,000 shares thus far today, vs. average volume of 331,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.5%) and underperformed the S&P 500 (-6.9% to the S&P's 0.5%) during today's trading.
VICL: 1.03 (+0.02)

Is Novavax Really Worth 25 Times As Much As Vical?
Intrepid Investor - at Seeking Alpha - Mon Dec 15, 11:08AM CST

VICL: 1.03 (+0.02), NVAX: 5.81 (+0.18)

Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 1.03 (+0.02), NNVC: 2.68 (-0.14)

Agenus: Herpes Competition And Cancer Checkpoint Prospects
William Meyers - at Seeking Alpha - Thu Dec 11, 11:06AM CST

AGEN: 3.85 (unch), VICL: 1.03 (+0.02), MRK: 57.46 (+0.25), GNCA: 7.42 (-0.11)

Vical Completes Enrollment in Its Therapeutic HSV-2 Vaccine Clinical Trial
GlobeNewswire - Thu Dec 11, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), the predominant cause of recurrent genital herpes. The enrollment was completed on schedule as originally planned. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy of two vaccine candidates (one encoding glycoprotein D alone and the other in combination with UL46). The study is powered to show at least a 30% decrease in the viral shedding rate following 3 doses of vaccine. A total of 165 otherwise healthy HSV-2- infected patients aged 18 to 50 years were enrolled across seven U.S. trial sites. The Company expects to release efficacy data by the middle of 2015.
VICL: 1.03 (+0.02)

Vical to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, December 2, at 1:30 p.m. ET at the Piper Jaffray 26 Annual Healthcare Conference (New York, December 2- 3). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.03 (+0.02)

Vical to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Tue Nov 11, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, November 18, at 4:10 p.m. ET at the Stifel 2014 Healthcare Conference (New York, November 18 - 19). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.03 (+0.02)

Vical's (VICL) CEO Vijay Samant on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 12:22AM CDT

VICL: 1.03 (+0.02)

Vical updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:34PM CDT

VICL: 1.03 (+0.02)

Vical Reports Third Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Oct 30, 6:10AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and nine months ended September 30, 2014. The net loss for the third quarter of 2014 was $4.4 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the third quarter of 2013. Revenues for the third quarter of 2014 were $3.4 million, compared with revenues of $1.5 million for the third quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. for development and manufacturing services performed under our ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
VICL: 1.03 (+0.02)

Vical EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:40AM CDT

VICL: 1.03 (+0.02)

SCG, CETV, VICL Expected To Be Down Before Next Earnings Releases
M2 - Mon Oct 27, 4:33AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. SCANA Corp (NYSE:SCG), Central European Media Enterprises Ltd (NASDAQ:CETV), Vical Inc (NASDAQ:VICL) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
VICL: 1.03 (+0.02), CETV: 3.04 (+0.12), SCG: 61.32 (+1.42)

Vical reports October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 12:12PM CDT

VICL: 1.03 (+0.02)

Vical Announces News Release and Conference Call Schedule for Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and nine months ended September 30, 2014, before the opening of trading on Thursday, October 30, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, October 30. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
VICL: 1.03 (+0.02)

HSV-2 Vaccine: Pharmaceutical Giant and Biotech Firm Join Forces; CBCD Commends Sanofi Pasteur (SNY) and Immune Design (IMDZ)
PRWeb - Tue Oct 21, 11:02PM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
VICL: 1.03 (+0.02), IMDZ: 34.96 (+0.78), GSK: 42.85 (+0.11)

Global Gene Therapy Market & Pipeline Insight Report 2014 - Analysis of 315 Drug therapy Pipelines for the $500 Million Market
M2 - Fri Oct 17, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nk3sv/global_gene) has announced the addition of the "Global Gene Therapy Market & Pipeline Insight" report to their offering. The global market opportunity for gene therapy is expected to reach USD 500 million by 2020 There have been significant advancements in the area of gene therapy in terms of research of new drugs. Over the past 20 years, the gene therapy market has witnessed significant advances ranging from the stage of conception, to the current stage of clinical trials for various disease conditions. When compared to other conventional methods such as radiotherapy and chemotherapy, gene therapy enjoys a clear advantage mainly because this therapy does not inhibit the immune system. Also, there has been an increased use of innovative technologies, which has led to an expansion of the scope of gene therapy worldwide. The growth of this market greatly depends on the regulatory approval of products which are currently in clinical trials. A major part of the gene therapy products for cancer and cardiovascular diseases are currently in Phase II and Phase III of clinical trials. Other factors impacting the gene therapy market are the cost of the treatment and the disease population under study. Additionally, funding and developments in research coupled with acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future. Although the initial studies of gene therapy were conducted mostly on monogenetic diseases, the focus of the scientists rapidly shifted towards cancer. This increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for dominant share in the overall clinical trials being conducted. The major reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. Global Gene Therapy Market & Pipeline Insight Market Highlight: - Gene Therapy Market Overview - Significance of Gene Therapy in Cancer Therapeutics - Current Applications of Gene Therapy to Cancer Treatment - Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook - FDA & AMA Guidelines for Gene Therapy - Gene Therapy Pipeline by Phase, Indications, Country & Company - Gene Therapy Pipeline: 246 Drugs - Marketed Gene Therapy: 2 (Gendicine & Rexin-G) - Cancer Gene Therapy Pipeline: 69 Drugs Key Topics Covered: 1. Introduction to Gene Therapy 2. Gene Therapy Classification 3. Mechanism of Gene Therapy 4. Global Gene Therapy Market Overview 5. Significance of Gene Therapy in Cancer Therapeutics 6. Current Applications of Gene Therapy to Cancer Treatment 7. Global Gene Therapy Market Dynamics 8. Gene Therapy Market Future Growth Outlook 9. EMA Guidelines for Gene Therapy 10. FDA Guidelines for Gene Therapy 11. Gene Therapy Pipeline by Phase, Indications, Country & Company 12. Marketed Gene Therapies by Indications, Country & Company 13. Suspended & Discontinued Gene Therapy in Pipeline 14. Competitive Landscape - Advantagene - BioCancell - Celgene - Epeius Biotechnologies - GenVec - Genethon - Introgen Therapeutics - MultiVir - Shenzhen SiBiono GeneTech - Vical - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/2n...lobal_gene
VICL: 1.03 (+0.02), ZIOP: 4.76 (+0.07), CELGZ: 3.34 (-0.01)

Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:43AM CDT
Vical Incorporated (VICL) was a big mover last session, as the company saw its shares rise 12% on the day.
VICL: 1.03 (+0.02), EBS: 27.64 (+1.28), FCSC: 2.38 (+0.04), EPZM: 17.71 (+0.01)

Stock to Watch: Vical Up 15.1% (VICL)
Comtex SmarTrend(R) - Mon Oct 13, 11:37AM CDT
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 15.1% to $1.24 on 8.1x average daily volume. Vical has traded 3.7 million shares thus far today, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (15.1% to the Dow's -0.3%) and outperformed the S&P 500 (15.1% to the S&P's -0.5%) during today's trading.
VICL: 1.03 (+0.02)

Vical Granted Six U.S. Patents for HSV-2 Vaccines
GlobeNewswire - Wed Oct 08, 5:36AM CDT
Vical Incorporated (Nasdaq:VICL) announced today the issuance of six U.S. patents that provide broad coverage of DNA vaccines for herpes simplex virus type 2 (HSV-2), containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant. These patents resulted from collaboration with the laboratories of leading HSV experts Drs. David Koelle and Lawrence Corey at the University of Washington under a multi-year NIH grant. The intellectual property is jointly owned by the University of Washington and Vical.
VICL: 1.03 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 72

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 81

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 15

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 71

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 34

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading

Top 5 Most Recently Viewed Articles

Carvana's Stock Peaks at $187.37 Amid Renewed Investor Confidence

Updated Category News Views 79

Carvana's Impressive Stock Surge to 52-Week High Recently, Carvana Co (NYSE: CVNA) achieved a remarkable milestone by hitting a 52-week high of $187.37. This surge highlights a robust recovery for the online used car retailer, whose stock has skyrocketed by an impressive 377.82% over the past year. This surge in stock price signifies renewed investor confidence in...

Continue Reading
ABM Industries Closes Q3 with Strong Earnings and Growth Boost

Updated Category News Views 133

ABM Industries Reports Strong Q3 Earnings ABM Industries (NYSE: ABM) saw its share price jump nearly 7% following the announcement of its third quarter earnings, which exceeded analyst expectations and prompted an upgrade to its full-year guidance. This positive outcome underscores the company's resilience in a challenging market landscape. Robust Financial Performance In...

Continue Reading
Transforming Senior Care: Click Holdings Embraces Cryptocurrency

Updated Category News Views 144

Innovative Strategies in Senior Care by Click Holdings Limited Click Holdings Limited (NASDAQ: CLIK) is making headlines with its groundbreaking approach to enhancing senior care services. Based in Hong Kong, this company combines cutting-edge human resources solutions with innovative cryptocurrency strategies, aiming to redefine how care services operate in an evolving...

Continue Reading
Cypress Creek and Meta Join Forces for Major Solar Project

Updated Category News Views 360

Cypress Creek and Meta's Renewable Energy Partnership In an exciting development, Cypress Creek Renewables and Meta have reached a significant milestone through their new Environmental Attribute Purchase Agreement (EAPA). This agreement is set to pave the way for the construction of a massive 505MWdc solar facility named Hanson Solar. With a capacity of 396MWac, this...

Continue Reading
The Shipyard Sets Sail with San Diego Headquarters Expansion

Updated Category News Views 462

The Shipyard Sets Sail with San Diego Headquarters Expansion The Shipyard, one of the fastest-growing independent marketing agencies in the nation, has announced an exciting development. The agency is expanding its operations by opening a new headquarters located in downtown San Diego at 185 West F Street. This move signifies a deepening of their commitment to California,...

Continue Reading